Ziliang Huang

Ziliang Huang

Auto-generated profile, based on publicly available information

Ziliang Huang

Alfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
ZHZiliang Huang
Ziliang Huang
YWYiqian Wu
Yiqian Wu
MAMolly E. Allen
Molly E. Allen
YPYijia Pan
Yijia Pan
PKPhillip Kyriakakis
Phillip Kyriakakis
YWYingxiao Wang
Yingxiao Wang
Light-sensitive regulators were engineered to control genetic induction of CAR expression in T cells for cancer immunotherapy.

1 December 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYiqian Wu
Yiqian Wu
ZHZiliang Huang
Ziliang Huang
YLYahan Liu
Yahan Liu
PHPeixiang He
Peixiang He
YWYuxuan Wang
Yuxuan Wang
YWYingxiao Wang
Yingxiao Wang
There remains a critical need for the precise control of CRISPR (clustered regularly interspaced short palindromic repeats)-based technologies. Here, we engineer a set of inducible CRISPR-based tools controllable by focused ultrasound (FUS), which can penetrate deep and induce localized hyperthermia for transgene activation. We demonstrate the capabilities of FUS-inducible CRISPR, CRISPR activation (CRISPRa), and CRISPR epigenetic editor (CRISPRee) in modulating the genome and epigenome. We show that FUS-CRISPR-mediated telomere disruption primes solid tumours for chimeric antigen receptor (CAR)-T cell therapy. We further deliver FUS-CRISPR in vivo using adeno-associated viruses (AAVs), followed by FUS-induced telomere disruption and the expression of a clinically validated antigen in a subpopulation of tumour cells, functioning as “training centers” to activate synthetic Notch (synNotch) CAR-T cells to produce CARs against a universal tumour antigen to exterminate neighboring tumour cells. The FUS-CRISPR(a/ee) toolbox hence allows the noninvasive and spatiotemporal control of genomic/epigenomic reprogramming for cancer treatment.

18 January 2022 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
YWYiqian Wu
Yiqian Wu
ZHZiliang Huang
Ziliang Huang
RHReed Harrison
Reed Harrison
LLLongwei Liu
Longwei Liu
LZLinshan Zhu
Linshan Zhu
YWYingxiao Wang
Yingxiao Wang
Despite its success in treating hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy faces two major challenges which hinder its broader applications: the limited effectiveness against solid tumors and the nonspecific toxicities. To address these concerns, researchers have used synthetic biology approaches to develop optimization strategies. In this review, we discuss recent improvements on the CAR and other non-CAR molecules aimed to enhance CAR T cell efficacy and safety. We also highlight the development of different types of inducible CAR T cells that can be controlled by environmental cues and/or external stimuli. These advancements are bringing CAR T therapy one step closer to safer and wider applications, especially for solid tumors.

31 October 2025 in Nature Materials
Verified
Journal Article
Open access
PDF file
CYChi Woo Yoon
Chi Woo Yoon
CSChunyang Song
Chunyang Song
DNDung Ngo Minh Nguyen
Dung Ngo Minh Nguyen
XYXi Yu
Xi Yu
LZLinshan Zhu
Linshan Zhu
YWYingxiao Wang
Yingxiao Wang
Cell-based cancer immunotherapy holds potential as a therapeutic approach, yet its application for solid tumour treatment remains challenging. Here we report a focused-ultrasound-based approach that mechanically induces the localized expression of CD19 antigen within a subpopulation of cells within solid tumours, which function as local ‘training centres’ to activate chimeric antigen receptor T cells. Activated chimeric antigen receptor T cells attack the whole cancer cell population near the tumour site, thus achieving cancer suppression. The system achieves targeted gene expression by integrating focused-ultrasound-triggered mechanical stimulation and the subsequent calcium response of cancer cells with a doxycycline-gated AND-logic genetic circuit, both of which need to be active for effective induction of CD19 expression. We validate the functionality of the approach in vitro, in organoids and in vivo, achieving direct control of user-designed gene expressions through FUS-mediated mechanical stimulation without the need of any cofactor, demonstrating the approach’s potential as a versatile platform for precisely controllable immunotherapy. Overall, our combinatorial approach offers a focused-ultrasound-controlled remote and non-invasive priming of solid tumours for effective and safe chimeric antigen receptor T cell immunotherapy via the induced production of clinically validated antigens.

1 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CYChi Woo Yoon
Chi Woo Yoon
CSChunyang Song
Chunyang Song
DNDung Ngo Minh Nguyen
Dung Ngo Minh Nguyen
LZLinshan Zhu
Linshan Zhu
PHPhuong Ho
Phuong Ho
YWYingxiao Wang
Yingxiao Wang
Cell-based cancer immunotherapy holds potential as a therapeutic approach, yet its application for solid tumor treatment remains challenging. We created a system where focused ultrasound (FUS) is able to remotely stimulate gene expressions in a specific tissue area through mechanical induction, gated by a chemical inducer to minimize the background noise. This system, known as CaDox, integrates FUS-triggered mechanical and calcium stimulation with doxycycline-responsive genetic circuits, which allows the localized expression of the clinically validated and specific antigen CD19 within a subpopulation of cancer cells upon FUS stimulation. These CD19-expressing cells can then function as “training centers” that activate synNotch chimeric antigen receptor (CAR) T cells to generate CARs that recognize a less specific but widespread antigen in cancer cells, thereby attacking and suppress the whole cancer cell population nearby at the tumor site. We validated the functionality of this CaDox system in vitro , in organoids, and in vivo , demonstrating its potential for various cell types and as a versatile platform for precisely controllable immunotherapy. Our combinatorial approach thus offers a FUS-controlled remote and non-invasive priming of solid tumors for effective and safe CAR T immunotherapy via the induced production of clinically validated antigens.

19 March 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZHZiliang Huang
Ziliang Huang
PLPraopim Limsakul
Praopim Limsakul
YWYiqian Wu
Yiqian Wu
TGTianze Guo
Tianze Guo
YWYuxuan Wang
Yuxuan Wang
YWYingxiao Wang
Yingxiao Wang
Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved clinical success, but remains limited in solid tumors by antigen escape and tumor heterogeneity. Here, we engineer a high-affinity R-phycoerythrin (PE)-binding monobody to create a PE-programmable CAR toward user-defined antigens sequentially or simultaneously. To reduce off-tumor toxicity, we implement a drug-gated light-activation approach (DGLA) strategy to spatially confine CAR function. We further couple DGLA-controlled tumor antigen presentation with synNotch-mediated programmable antigen-targeting CAR (sPAT) to establish programmable CAR-antigen pairing (DGLA-sPAT). This system induces clinically validated antigens on tumor cells as local ‘training centers’ that recruit and activate sPAT CAR T cells, enabling elimination of entire tumor populations through broadly expressed tumor antigens using PE-conjugated antibodies. In vivo, DGLA-sPAT manifests local T cell activation and potent tumor suppression with minimal off-tumor toxicity. Thus DGLA-sPAT provides a modular and spatially controlled framework to overcome antigen escape and heterogeneity while improving safety in solid-tumor CAR-T therapy.